Intravenous iron for the treatment of fatigue in nonanemic, premenopausal women with low serum ferritin

impact of iron status on response to darbepoetin alfa in patients with chemotherapy induced anemia. Blood 2009; 114: abstract 2007. 6. Steinmetz HT, Tsamaloukas A, Schmitz S et al. A new concept for the differential diagnosis and therapy of anaemia in cancer patients. Support Care Cancer 2010; 19: 261–269. 7. National Comprehensive Cancer Network Inc. NCCN Practice Guidelines in Oncology; Cancer and chemotherapy-Induced Anemia—v.2.2012; http://www. nccn.org/professionals/physician_gls/f_guidelines.asp (7 March 2013, date last accessed). 8. Aapro M, Osterborg A, Gascon P et al. Prevalence and management of cancerrelated anaemia, iron deficiency and the specific role of i.v. iron. Ann Oncol 2012; 23: 1954–1962. 9. Beguin Y. Prediction of response and other improvements on the limitations of recombinant human erythropoietin therapy in anemic cancer patients. Haematologica 2002; 87: 1209–1221. 10. Wish JB. Assessing iron status: beyond serum ferritin and transferrin saturation. Clin J Am Soc Nephrol 2006; 1: S4–S8. 11. Brownlie T, Utermohlen V, Hinton PS et al. Tissue iron deficiency without anemia impairs adaptation in endurance capacity after aerobic training in previously untrained women. Am J Clin Nutr 2004; 79: 437–443. 12. Verdon F, Burnand B, Stubi CL et al. Iron supplementation for unexplained fatigue in non-anaemic women: double blind randomised placebo controlled trial. BMJ 2003; 326: 1124–1126. 13. Krayenbuehl PA, Battegay E, Breymann C et al. Intravenous iron for the treatment of fatigue in nonanemic, premenopausal women with low serum ferritin concentration. Blood 2011; 118: 3222–3227. 14. Anker SD, Comin CJ, Filippatos G et al. Ferric carboxymaltose in patients with heart failure and iron deficiency. N Engl J Med 2009; 361: 2436–2448. 15. Auerbach M, Ballard H, Trout JR et al. Intravenous iron optimizes the response to recombinant human erythropoietin in cancer patients with chemotherapy-related anemia: a multicenter, open-label, randomized trial. J Clin Oncol 2004; 22: 1301–1307. 16. Gafter-Gvili A, Rozen-Zvi B, Vidal L et al. Intravenous iron supplementation for the treatment of chemotherapy-induced anemia—systematic review and metaanalysis of randomized controlled trials. Acta Oncol 2013, 52: 18–29. 17. Weiss G, Goodnough LT. Anemia of chronic disease. N Engl J Med 2005; 352: 1011–1023. 18. Robertson KA, Hutchinson SM. Assessment of iron status and the role for ironreplacement therapy in anaemic cancer patients under the care of a specialist palliative care unit. Palliat Med 2009; 23: 406–409. 19. Spielmann M, Luporsi E, Ray-Coquard I et al. Diagnosis and management of anaemia and iron deficiency in patients with haematological malignancies or solid tumours in France in 2009–2010: the AnemOnHe study. Eur J Cancer 2011; 48: 101–107. 20. Ludwig H, Aapro M, Beguin Y et al. Frequent use of blood transfusions in current treatment practice for chemotherapy-induced anemia counteracts treatment recommendations aiming for less transfusions. Haematologica 2011; 96: abstract 407. 21. Bruner AB, Joffe A, Duggan AK et al. Randomised study of cognitive effects of iron supplementation in non-anaemic iron-deficient adolescent girls. Lancet 1996; 348: 992–996.